Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)

…18% today on the hope of a fruitful FDA decision later this week. With that in mind, it’s important to look at how hedge funds and insiders have been trading it of late.

Stocks Review: VIVUS, Inc.(NASDAQ:VVUS), Amgen, Inc. (NASDAQ:AMGN), Lincoln National Corporation(NYSE:LNC) (Meshpress)
VIVUS, Inc. (NASDAQ:VVUS) shares climbed 3.88% to $11.25. First Manhattan Co. (FMC), an owner-operated investment advisory firm and the beneficial holder of approximately 9.1 percent of the outstanding shares of VIVUS, Inc. (“Vivus”), on April 10 issued a statement in anticipation of the expected announcement from VIVUS, Inc. (NASDAQ:VVUS) that its obesity treatment Qsymia has received a modification in its Risk Evaluation and Mitigation Strategy (REMS). Additionally, the company, on March 26, announced that it has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors.

April 27: Mayor’s Ride to Kick Off Amgen Bike Tour (SCVNews.com)
Santa Clarita community members are invited to join Mayor Bob Kellar for a free community bike ride beginning at 8:30 a.m. on Saturday, April 27, at the Iron Horse Trailhead located off of Magic Mountain Parkway near Tourney Road. The Mayor’s Ride will kick off a series of events surrounding the 2013 Amgen, Inc. (NASDAQ:AMGN) Tour of California professional cycling race, which is set to ride through Santa Clarita on Tuesday, May 14 and Wednesday, May 15, 2013. The Mayor’s Ride is a family friendly event where riders of any level can participate.

Acorda Therapeutics Price Target Raised to $40.00 at Aegis (ACOR) (Zolmax)
Equities researchers at Aegis boosted their target price on shares of Acorda Therapeutics Inc (NASDAQ:ACOR) from $34.00 to $40.00 in a report issued on Monday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Shares of Acorda Therapeutics (NASDAQ: ACOR) traded up 9.20% during mid-day trading on Monday, hitting $34.42. Acorda Therapeutics has a one year low of $21.04 and a one year high of $32.92. The stock’s 50-day moving average is currently $30.73. The company has a market cap of $1.386 billion and a P/E ratio of 8.21.

Myriad Genetics (NASDAQ: MYGN) Could Get Crushed (Wealth Daily)
This week the Supreme Court will provide an oral hearing to decide whether or not the gene patents should be allowed. This is based on a challenge of Myriad Genetics, Inc. (NASDAQ:MYGN), which currently holds patents on a variety of genes linked primarily to ovarian and breast cancer. The Supreme Court will hear a host of arguments in the coming week, including those from doctors, cancer survivors, patients, and scientists, all of whom feel as if genes should not be allowed to be patented by corporations. A decision in the case is expected to be completed by June 2013.